Peptide science at the intersection of diet, metabolism, and performance.

Peptidegenics

An independent reference on how peptides interact with diet, metabolism, body composition, and training. No supplements sold. No affiliates. No agenda.

Browse by Metabolic Context

All contexts →
Caloric Deficit & Fat Loss

How peptides affect fat oxidation, muscle retention, and metabolic rate during energy restriction.
Anabolic Environment & Muscle

Growth hormone axis peptides, mTOR, protein synthesis, and what training stimulus has to do with it.
Fasting & Metabolic Switching

Peptide interactions with fasting windows, ketosis, autophagy, and insulin signalling.
Performance & Recovery Nutrition

Pre- and post-training peptide timing, recovery nutrition context, and substrate utilisation.

Latest Articles

View all →
Metabolic Performance Extrapolated

Does Combining Retatrutide With Cagrilintide Amplify Fat Loss and Glucose Control Through Complementary Multi-Receptor Signaling in 2026?

The September 2026 Nature Metabolism study (Petersen et al., PMID 42744908) shows that combining retatrutide, a GLP-1R/GIPR/GCGR tri-agonist, with cagrilintide, a long-acting amylin/calcitonin receptor agonist, produces greater fat loss and improved cholesterol, triglycerides, and insulin versus either compound alone in obese male rats. The mechanistic rationale is receptor non-overlap: incretin and amylin pathways engage distinct neural and peripheral circuits.

October 21, 2026 · 9 min read
Metabolic Performance Extrapolated

Does Adding Trevogrumab to Semaglutide Preserve More Lean Mass Without Sacrificing Fat Loss in 2026?

In the Phase 2 COURAGE trial, semaglutide 2.4 mg alone lost approximately 7 kg fat and 3 kg lean mass over 26 weeks, with roughly 35% of total weight loss from lean tissue. Adding trevogrumab (anti-GDF8/myostatin) cut lean-mass loss by approximately half while amplifying fat-mass reduction, without attenuating total weight loss or metabolic benefits.

October 21, 2026 · 9 min read
Metabolic Performance Extrapolated

How Much Lean Mass Can High-Protein Intake and Resistance Training Actually Protect During Retatrutide's 28% Weight Loss in 2026?

At retatrutide's weight loss of 28 percent (TRIUMPH-1, 80 weeks), calorie restriction alone loses roughly 35 percent of total weight as lean tissue, approximately 9–11 kg on a 90 kg baseline. Combining resistance training with protein at or above 1·6 g/kg/day can reduce that lean fraction to 10–15 percent, protecting an estimated 6–9 kg. No retatrutide-specific RCT confirms this arithmetic.

October 15, 2026 · 9 min read
Metabolic Performance Extrapolated

What Do TRIUMPH-2's 80-Week Phase 3 Results Reveal About Retatrutide's Fat-Versus-Lean-Mass Partitioning in Adults With Type 2 Diabetes in 2026?

TRIUMPH-2's 80-week Phase 3 data show retatrutide at 12 mg produced 20.8% mean body-weight loss in adults with type 2 diabetes — 7.5 percentage points below non-diabetic TRIUMPH-1. The 2025 Coskun DXA sub-study found lean mass comprised approximately 35% of weight lost in the T2D population, driven by compounded anabolic resistance and a pre-existing sarcopenic phenotype.

October 14, 2026 · 9 min read
Preclinical Extrapolated

What Does the 2026 Rodent IRI Histological Evidence for BPC-157 Show About Muscle Architecture Preservation — and What Does That Mean for Metabolic Performance?

Yıldırım et al. (Scientific Reports, 2026) documented that BPC-157 at 20 µg/kg IP improved skeletal muscle architecture on Masson-trichrome staining, reduced collagen deposition, and significantly lowered caspase-3 and IL-6 immunohistochemical expression versus untreated IRI controls. These structural findings extend the 2026 Demirtaş critical review's oxidative biomarker data into tissue-level morphology — exclusively in rodent models with no validated human translation.

October 13, 2026 · 10 min read
Metabolic Performance Extrapolated

How Much Lean Mass Does Resistance Training Actually Preserve During GLP-1 Treatment in 2026?

Resistance training materially preserves lean mass during GLP-1 treatment. The Karakasis 2025 meta-analysis found GLP-1 monotherapy loses approximately 25% of total weight as lean tissue; exercise-combined arms cut that fraction to roughly 10–15%. On a 15 kg semaglutide weight-loss course, structured training can prevent 2–4 kg of lean tissue loss, a 60–70% reduction in lean mass attrition.

October 8, 2026 · 9 min read
75%
mean increase in IGF-1 levels with CJC-1295 at 12 weeks
— Teichman et al., 2006, JCEM

Browse by Category

All Articles Clinical Review Metabolic Metabolic Longevity Metabolic Nutrition Metabolic Oncology Metabolic Performance Metabolic Signalling Preclinical Regulatory

About Peptidegenics

Learn more →

Peptidegenics covers the intersection of peptide biochemistry, nutrition science, and metabolic physiology. Every article is grounded in published research. Nothing is sold here.

The Metabolic Applicability Rating on each article answers the question the performance-focused reader actually asks: does this evidence apply to how I actually eat and train, or is this a lab finding I cannot act on?

About this publication  ·  Editorial policy & the Metabolic Applicability Rating →